ClinicaliQ Trial Snapshot
- Nipocalimab in Moderate to Severe Sjogren’s Disease — Active Not Recruiting • Phase III • NCT06741969.
- Nipocalimab injection appears safe and effective for treating moderate to severe Sjögren's disease symptoms.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD). Conditions: Sjogrens Syndrome Interventions: Nipocalimab, Placebo, Standard of care treatment Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 655 participants